Diagnos Inc (ADK)

Well, here we go,friends and neighbors. I just put an order in to sell 10% of my 500,000 shares of this TURKEY. I will be more than happy if they see fit, to give me a 1.47 a share.

I have been here since 2017. This thing was an AI play before I knew what AI was. This could one day be a company with 250 million dollars a year in profit. But it is stuck in neutral. It is the same as a drug company a long time ago that had a drug that was used all over the world, even in Europe. Where the laws are much stricter than here. But, alas, if the right people are not in it. It will not happen. We now have the same thing. Proven product in many parts of the world. But going no where. Now we have a new set of people that look like they may be able to push it over the finish line. I write this all down for no one but me. Now, once again we have a Friday buy rule. Will it fail once again ? I know not. But if it takes off. I be fully loaded.
Best of luck to all.

Yes it’s definitely starting to go up hill.
Currently $0.26

Buckle up Bucke, here we go. Only took 5 years.

She be breaking out. Time to get on.

I be die hard. I buy more.

The only way for this to go up. Is for me to sell my shares.

I feel like the Maytag repair man.

It be time to BUY more.

I BOUGHT SOME MORE. Looks like it wants to break out.

I am a die hard, just bought more.

I just bought some more.

When every one leaves is when they go up.

Looking a little better.

Nice brake out. But no volume. Maybe it is so good, no one wants to sell.

It is about time. Breaking out. Maybe, just maybe, it is going to work.

Then again, maybe NOT.

It looks like this is coming back to life.

DIAGNOS Inc. TSX-V: ADK Increasingly In-play with Two Major Catalysts; Clinical trials on Stroke Predictor have begun at 2nd largest health service provider in USA, and worlds largest eyecare company is in negotiations for platform access. See recent Market Bulletin https://marketequitiesresearch.com/marketbulletin-diagnos-advisory-dec-2021.htm

DIAGNOS' AI-Driven Retinal Analysis Technology is in the Process of Transforming Industries -- DIAGNOS Inc. is the subject of a Technology Marketwatch Journal review, the full copy of which may be viewed at https://technologymarketwatch.com/adk.htm online.

Excerpt copy:
DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based medical software technology company that pioneered 'Computer Assisted Retinal Analysis' (CARA), which automatically analyses the retina (located at the back of the eye) using machine learning / artificial intelligence (AI) technology to identify damage caused by diabetes and cardiovascular issues. For the last 7 years DIAGNOS has commercially advanced its first large-scale application of the technology, primarily aimed at preventing diabetic retinopathy. Entering 2022 marks a pivotal time for DIAGNOS as the technology has recently seen several large players in the eyecare sector and medical field commit to large-scale roll-outs, this is putting pressure on others in the sector to consider a similar move and not be left behind. DIAGNOS' technology essentially transforms eyecare centers into Point of Care and wellness diagnostic centers as the CARA platform also is expected to commercially launch several other large-scale applications, including an application for hypertensive retinopathy (launch imminent) and one for stroke prediction (undergoing clinical trials now in USA). Complicated medical conditions resulting from diabetes, high blood pressure, and potential stroke can be detected by DIAGNOS' algorithms able to interpret detailed imagery of the retina. Since New Look (with 407 locations in Canada) signed on for CARA platform roll-out DIAGNOS' phone has been ringing from around the globe, essentially other industry participants do not want to miss out on a technology whose time has come. Look for an increase in new business announcements to come from the DIAGNOS over the coming months and years. In fact, Essilor Luxottica (Euronext Paris Stock exchange: EL), the largest eyecare company in the world, with EUR$16+ Billion in revenue and ~15,000 locations, signed a MOU with DIAGNOS in August-2021 and is in active negotiations on terms -- this alone has massive latent catalyst potential for upside share price revaluation of ADK.V as details emerge. Specifically DIAGNOS and Essilor are currently negotiating 3 things; 1) contract for the existing platform, 2) Essilor wants DIAGNOS to do a specific development for their line of fundus camera, and 3) Essilor wants access to future applications DIAGNOS will roll out. The fact the largest eyecare company in the world chose DIAGNOS' technology speaks volumes as to where this is headed.
 
With all the activity DIAGNOS has on the go it appears a low-risk high-reward proposition: ADK.V only has 69.12 million shares outstanding, there are very little warrants left, and insiders & family office own ~40% of the outstanding shares. DIAGNOS has no debt, money in the bank, an untapped C$2 million government credit line if needed, has a high-margin SaaS model (it only costs ~4 cents to process an image that it charges between ~C$5 - $10), is expected to be cash flow positive (based on solid contracts) in the coming fiscal year, has numerous new business prospects in discussion now, and is expected to see rapid revenue growth. Astute investors connecting the dots about what is unfolding are apt to do well by establishing a long position in ADK.V now.

DIAGNOS Inc. received its first institutional coverage from the independent investment bank / advisory / equity research firm Echelon Capital Markets, its current rating is 'Top Pick', 'Speculative BUY' with a near-term (12 month) target price per common share of DIAGNOS of $1.55 Canadian (or in US dollars: USD$1.23 or in Euros: €1.09) -- click here to view full copy of their latest report. The original initiating report was exceptionally thorough (~40 pages), the analyst contacted multiple industry participants, and recently (November-2021) sat down for an interview [running time 32 min. Youtube] on his reasoning for making it a top pick entering 2022.
 
------ ------ ------ ------ ------ ------ ------ ------ ------

Recommend reading: https://technologymarketwatch.com/adk.htm

DIAGNOS (TSXV: $ADK) (OTCQB: $DGNOF) (FRA: 4D4A) Announces Date of Annual General and Special Meeting of Shareholders
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
https://www.otcmarkets.com/stock/DGNOF/news/DIAGNOS-Announces-Date-of-Annual-General-and-Special-Meeting-of-Shareholders?id=316830

Nice little pop to start off the week, DIAGNOS (TSXV: $ADK) (OTCQB: $DGNOF) (FRA: 4D4A) Announces Date of Annual General and Special Meeting of Shareholders
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
https://www.otcmarkets.com/stock/DGNOF/news/DIAGNOS-Announces-Date-of-Annual-General-and-Special-Meeting-of-Shareholders?id=316830

$DGNOF News- DIAGNOS signs Memorandum of Understanding with Essilor International.
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
https://www.otcmarkets.com/stock/DGNOF/news/DIAGNOS-signs-Memorandum-of-Understanding-with-Essilor-International?id=316490

(TSXV: ADK) (OTCQB: DGNOF) (FRA: 4D4A) Market Analysis #UnderValued #Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq

https://www.dropbox.com/s/bjwq8yxyr7popcq/%24DGNOF%20%20%24ADK.pdf?dl=0

$DGNOF (TSXV: ADK) – DIAGNOS Announces a Pilot with Opticalia in Spain
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
https://www.otcmarkets.com/stock/DGNOF/news/DIAGNOS-Announces-a-Pilot-with-Opticalia-in-Spain?id=313555

$low n $teady, this is building nicely.

News next week? if so we should see a move higher imo

You keeping an eye on this, News starting to flow an the PPS is solid, chart reads HIGHER :)

$DGNOF – DIAGNOS Announces a Pilot with Opticalia in Spain
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
https://www.otcmarkets.com/stock/DGNOF/news/DIAGNOS-Announces-a-Pilot-with-Opticalia-in-Spain?id=313555

Beautiful play 34c to 65c fur 2900.00 profit. How much did you make.

Lastly all the s*** that he recommends or Canadian over the counter companies with no business no management no reporting

I haven't seen him right on one of these except for a little blip here in there where he probably sells his stock

Just follow him because everything he recommends goes down it's like the George Costanza episode in Seinfeld where he does the opposite of his initial thoughts just short everything that he recommends

This is a great short I've already shorted two or three others that he's recommended and made 40 to 80%

LOW VOLUME GARBAGE! SEVERE TOXIC RINSE!!!

ROFLMAO

Heading to no bid soon! Scam company!!!

Keeps going higher and higher

REVERSE SPLIT CONFIRMED!!!

Awesome week so far!! Great call TrendTrade2016. You know what you are talking about for sure. I appreciate the honesty- very rare on these boards. Cheers

Heading to NO BID!!!

LOLOL

TOXIC RINSE!!!

ROFLMAO

SCREAMING PUMP and DUMP!! Low volume garbage!!!

monster week...next week will be sick...watch and learn!!

watch her fly!!!

Too funny! Low volume pump and dump!!!

LOLOL

booom...look at her run....going to be epic...lmao!!

Fake news! SCAM ALERT!!!

Going to get very ugly here! Get ready for tax loss selling!!

PUMP and DUMP!!! REVERSE SPLIT any day!!

Get ready to rumble. Love this company.

ADK.V look out for this Canadian one of a kind AI Computer Assisted Retinal Analysis....FDA approved!!